MA35937B1 - Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium - Google Patents

Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium

Info

Publication number
MA35937B1
MA35937B1 MA37344A MA37344A MA35937B1 MA 35937 B1 MA35937 B1 MA 35937B1 MA 37344 A MA37344 A MA 37344A MA 37344 A MA37344 A MA 37344A MA 35937 B1 MA35937 B1 MA 35937B1
Authority
MA
Morocco
Prior art keywords
receptor modulators
substituted compounds
calcium receptor
relates
compounds
Prior art date
Application number
MA37344A
Other languages
English (en)
Inventor
Venkata P Palle
Rajender Kumar Kamboj
Manojkumar Ramprasad Shukla
Ankush Gangaram Sarde
Rajeshkumar Maganlal Loriya
Vipul Dilip Pachpute
Navnath Bajirao Walke
Talha Hussain Khan
Sanjeev Anant Kulkarni
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA35937B1 publication Critical patent/MA35937B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

La présente invention concerne des modulateurs des récepteurs de détection du calcium (casr). La présente invention concerne notamment des composés utiles pour le traitement, la prise en charge, et/ou l'atténuation de la gravité de maladies, de troubles, de syndromes et/ou d'affections associés à la modulation des récepteurs de détection du calcium (casr). La présente invention concerne également des compositions pharmaceutiques comprenant lesdits composés, ainsi que des procédés de traitement, de prise en charge, et/ou d'atténuation de la gravité de maladies, de troubles, de syndromes et/ou d'affections associés à la modulation des casr. L'invention concerne en outre un procédé de préparation des composés de l'invention.
MA37344A 2012-02-24 2014-09-10 Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium MA35937B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN178KO2012 2012-02-24
IN1030KO2012 2012-09-07
PCT/IB2013/051445 WO2013124828A1 (fr) 2012-02-24 2013-02-22 Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium

Publications (1)

Publication Number Publication Date
MA35937B1 true MA35937B1 (fr) 2014-12-01

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37344A MA35937B1 (fr) 2012-02-24 2014-09-10 Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium

Country Status (44)

Country Link
US (3) US9163001B2 (fr)
EP (1) EP2817299B1 (fr)
JP (1) JP6114316B2 (fr)
KR (1) KR102041154B1 (fr)
CN (1) CN104350047B (fr)
AP (1) AP2014007919A0 (fr)
AR (1) AR090135A1 (fr)
AU (1) AU2013223715B2 (fr)
BR (1) BR112014021133B1 (fr)
CA (1) CA2864332C (fr)
CL (1) CL2014002218A1 (fr)
CO (1) CO7160018A2 (fr)
CR (1) CR20140424A (fr)
CU (1) CU24325B1 (fr)
CY (1) CY1122017T1 (fr)
DK (1) DK2817299T3 (fr)
DO (1) DOP2014000193A (fr)
EA (1) EA026940B9 (fr)
ES (1) ES2743492T3 (fr)
GE (2) GEAP201813579A (fr)
GT (1) GT201400179A (fr)
HR (1) HRP20191606T1 (fr)
HU (1) HUE046172T2 (fr)
IL (1) IL234252A (fr)
IN (1) IN2014MN01672A (fr)
LT (1) LT2817299T (fr)
MA (1) MA35937B1 (fr)
MX (1) MX355670B (fr)
MY (1) MY171374A (fr)
NI (1) NI201400094A (fr)
NZ (1) NZ628627A (fr)
PE (1) PE20142281A1 (fr)
PH (1) PH12014501891B1 (fr)
PL (1) PL2817299T3 (fr)
PT (1) PT2817299T (fr)
RS (1) RS59172B1 (fr)
SG (1) SG11201405117SA (fr)
SI (1) SI2817299T1 (fr)
SM (1) SMT201900506T1 (fr)
TN (1) TN2014000352A1 (fr)
TW (1) TWI617549B (fr)
UA (1) UA112679C2 (fr)
WO (1) WO2013124828A1 (fr)
ZA (1) ZA201405990B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191606T1 (hr) * 2012-02-24 2019-12-13 Lupin Ltd Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij
CA2882039A1 (fr) * 2012-08-27 2014-03-06 Lupin Limited Composes d'arylalkylamine jouant le role de modulateurs des recepteurs sensibles au calcium
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
CA2920818A1 (fr) 2013-08-28 2015-03-05 Lupin Limited Composes de naphtalene substitue en tant que modulateurs du recepteur de detection de calcium
WO2015162538A1 (fr) 2014-04-21 2015-10-29 Lupin Limited Composés hétérocycliques en tant que modulateurs des récepteurs de détection du calcium pour le traitement de l'hyperparathyroïdie, de l'insuffisance rénale chronique et de la néphropathie chronique
WO2017037616A1 (fr) 2015-08-31 2017-03-09 Lupin Limited Composés d'arylalkylamine comme modulateurs des récepteurs sensibles au calcium
JP7764372B2 (ja) 2019-11-19 2025-11-05 ルピン・リミテッド クロマン化合物を調製する方法
CA3166210A1 (fr) * 2019-12-27 2021-07-01 Lupin Limited Composition pharmaceutique de modulateurs de casr et procedes et utilisations associes
MX2022008805A (es) 2020-01-17 2022-08-11 Lupin Ltd Metodos, procesos e intermedios para preparar compuestos cromanos.
WO2025255092A1 (fr) * 2024-06-03 2025-12-11 Artax Biopharma Inc. Combinaison d'un inhibiteur de tcr dérivé de chromène et d'un inhibiteur de tyk2

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0020018B1 (fr) * 1979-05-19 1983-06-01 Beecham Group Plc Dérivés de chromane, procédé pour leur préparation et compositions pharmaceutiques les contenant
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
WO2004069793A2 (fr) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Nouveaux amines cycliques substitues en position 2 comme modulateurs du recepteur de detection de calcium
WO2004106280A1 (fr) 2003-05-28 2004-12-09 Japan Tobacco Inc. Antagoniste de casr
CA2608957C (fr) 2005-05-19 2013-12-10 Astellas Pharma Inc. Derive de pyrrolidine ou son sel
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
CA2672956C (fr) * 2006-10-26 2015-02-10 Amgen Inc. Agents modulant le recepteur sensible au calcium
WO2008059854A1 (fr) 2006-11-16 2008-05-22 Astellas Pharma Inc. Dérivés de pipéridine ou sels de ceux-ci
WO2009051718A2 (fr) * 2007-10-15 2009-04-23 Amgen Inc. Agents de modulation du récepteur du calcium
US9487494B2 (en) 2007-11-23 2016-11-08 Leo Pharma A/S Cyclic hydrocarbon compounds for the treatment of diseases
WO2010038895A1 (fr) 2008-10-03 2010-04-08 味の素株式会社 Agoniste du casr
WO2010042642A1 (fr) 2008-10-08 2010-04-15 Amgen Inc. Agents modulateurs des récepteurs de calcium
EP2435404A1 (fr) 2009-05-27 2012-04-04 Leo Pharma A/S Nouveaux composés modulant le récepteur sensible au calcium, et leur utilisation pharmaceutique
WO2010150837A1 (fr) 2009-06-25 2010-12-29 第一三共株式会社 Dérivé de l'indoline
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
EP2643298A1 (fr) 2010-11-26 2013-10-02 Leo Pharma A/S Cyclopentylazines substituées en tant que composés casr-actifs
WO2012069419A1 (fr) 2010-11-26 2012-05-31 Leo Pharma A/S Composés actifs sur le récepteur sensible au calcium
CA2828415A1 (fr) 2011-03-10 2012-09-13 Lupin Limited Morpholines substituees en tant que modulateurs pour le recepteur de calcium
WO2012127385A1 (fr) * 2011-03-18 2012-09-27 Lupin Limited Dérivés benzo[b][1,4]oxazine en tant que modulateurs de récepteurs de détection de calcium
HRP20191606T1 (hr) * 2012-02-24 2019-12-13 Lupin Ltd Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij

Also Published As

Publication number Publication date
KR20140135731A (ko) 2014-11-26
DOP2014000193A (es) 2017-01-15
JP2015508097A (ja) 2015-03-16
GEP20186911B (en) 2018-10-25
HRP20191606T1 (hr) 2019-12-13
ZA201405990B (en) 2015-11-25
DK2817299T3 (da) 2019-09-16
TN2014000352A1 (en) 2015-12-21
AU2013223715A1 (en) 2014-08-28
SI2817299T1 (sl) 2019-10-30
US20170209410A1 (en) 2017-07-27
TW201336831A (zh) 2013-09-16
EP2817299A1 (fr) 2014-12-31
IL234252A (en) 2017-02-28
CU20140103A7 (es) 2015-01-29
CY1122017T1 (el) 2020-10-14
CU24325B1 (es) 2018-03-13
UA112679C2 (uk) 2016-10-10
NI201400094A (es) 2015-03-27
BR112014021133B1 (pt) 2022-06-28
GT201400179A (es) 2016-03-01
TWI617549B (zh) 2018-03-11
MX355670B (es) 2018-04-25
US9163001B2 (en) 2015-10-20
MX2014010139A (es) 2015-09-04
PH12014501891B1 (en) 2021-05-05
GEAP201813579A (en) 2018-06-25
IN2014MN01672A (fr) 2015-05-29
PH12014501891A1 (en) 2015-02-09
CA2864332A1 (fr) 2013-08-29
AR090135A1 (es) 2014-10-22
AU2013223715B2 (en) 2017-09-14
US9598391B2 (en) 2017-03-21
BR112014021133A2 (pt) 2018-09-11
CR20140424A (es) 2015-01-13
EA026940B1 (ru) 2017-06-30
US20150368222A1 (en) 2015-12-24
LT2817299T (lt) 2019-09-25
JP6114316B2 (ja) 2017-04-12
ES2743492T3 (es) 2020-02-19
MY171374A (en) 2019-10-10
SMT201900506T1 (it) 2019-11-13
EP2817299B1 (fr) 2019-06-12
EA201491582A1 (ru) 2014-12-30
KR102041154B1 (ko) 2019-11-07
CO7160018A2 (es) 2015-01-15
CN104350047B (zh) 2017-05-24
CL2014002218A1 (es) 2015-03-06
HUE046172T2 (hu) 2020-02-28
US9987249B2 (en) 2018-06-05
CA2864332C (fr) 2020-08-25
PT2817299T (pt) 2019-09-23
HK1205117A1 (en) 2015-12-11
US20150038546A1 (en) 2015-02-05
NZ628627A (en) 2017-02-24
PE20142281A1 (es) 2015-01-16
WO2013124828A1 (fr) 2013-08-29
EA026940B9 (ru) 2017-11-30
AP2014007919A0 (en) 2014-09-30
SG11201405117SA (en) 2014-09-26
CN104350047A (zh) 2015-02-11
PL2817299T3 (pl) 2019-12-31
RS59172B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
MA35937B1 (fr) Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA54231B1 (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
MA35459B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
MA42376B1 (fr) Dérivés d'oxopyridine substitués
MA35444B1 (fr) Ligands du récepteur ep1
MA37739B1 (fr) Composés et compositions destinés à la modulation de l'activité de l'egfr
MA40290A1 (fr) Agents immunorégulateurs
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
BR112012004453A8 (pt) composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA37888B1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
EA201490539A1 (ru) Соединения и композиции в качестве ингибиторов c-kit киназы
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA34474B1 (fr) Agonistes de gpr40
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA34724B1 (fr) Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase
MA35407B1 (fr) Modulateurs allostériques positifs des récepteurs nicotiniques d'acétylcholine
TN2011000669A1 (fr) L-serine pour son utilisation en tant que medicament pour prevenir et/ou traiter une reaction inflammatoire de la peau
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb